SYNACT PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.05 SEK | +3.15% |
|
+3.07% | -20.16% |
| Apr. 23 | Synact Pharma AB Announces Changes in Nomination Committee Ahead of the 2024 Annual General Meeting | CI |
| Mar. 20 | Sweden's SynAct Pharma Names New CEO | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 314M 3.41B |
|---|---|---|---|---|---|
| Net income 2022 | -99M -1.07B | Net income 2023 | -216M -2.34B | EV / Sales 2022 | - |
| Net cash position 2022 | 106M 1.15B | Net cash position 2023 | 61.76M 670M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-22.7
x | P/E ratio 2023 |
-1.33
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.39% | ||
| 1 week | +4.31% | ||
| Current month | +4.31% | ||
| 1 month | -9.51% | ||
| 3 months | -11.26% | ||
| 6 months | +0.49% | ||
| Current year | -19.20% |
1 week
6.55
7.16
1 month
6.558.14
Current year
4.9813.80
1 year
4.98124.60
3 years
4.98146.00
5 years
4.98146.00
10 years
4.75146.00
| Managers | Title | Age | Since |
|---|---|---|---|
Björn Westberg
DFI | Director of Finance/CFO | 62 | 23-05-31 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | Feb. 14 |
Thomas Boesen
COO | Chief Operating Officer | - | 21-01-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Jonassen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 7.05 | +3.15% | 116 602 |
| 24-05-06 | 6.835 | +2.70% | 105,821 |
| 24-05-03 | 6.655 | -2.35% | 149,840 |
| 24-05-02 | 6.815 | -0.37% | 90,634 |
| 24-04-30 | 6.84 | -0.94% | 59,685 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 08:53 am EDT
More quotes
SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
Calendar
2024-05-16
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -19.20% | 26.12M | |
| +22.81% | 46.81B | |
| -1.88% | 41.37B | |
| +46.79% | 41.29B | |
| -6.20% | 28.87B | |
| +11.33% | 26.06B | |
| -21.00% | 19.13B | |
| +30.73% | 12.39B | |
| -0.48% | 12.08B | |
| -1.43% | 11.96B |
- Stock Market
- Equities
- SYNACT Stock